
Respiratory tract infections remain among the most common acute illnesses globally, ranging from self-limiting upper respiratory tract infections to serious lower respiratory tract infections including pneumonia and bronchitis. Antimicrobial stewardship is central to appropriate management and resistance containment. RSV prevention with long-acting monoclonal antibody nirsevimab and new adult RSV vaccines represents a major 2023–2024 advance in this space.
